UNSPSC 41151625: Refractometer for clinical use

In this classification a refractometer for clinical use is a device intended to determine the amount of solute in a solution by measuring the index of refraction (the ratio of the velocity of light in a vacuum to the velocity of light in the solution). The index of refraction is used to measure the concentration of certain analytes (solutes), such a plasma total proteins and urinary total solids. US FDA regulates Refractometer for clinical use under 21 CFR 862.2800 and under FDA product code JRE.

UNSPSC 41151625 Refractometer for clinical use is a Commodity code that state and local governments rarely procure through direct solicitation. The recent opportunities block contains no solicitations seeking refractometers for clinical use; the listed opportunities address laboratory and analytical equipment across completely different product families—including mass spectrometers, chromatography systems, aerodynamic testing equipment, motion-capture systems, rheometers, nitrogen generators, and specialized research instruments—but none involve clinical refractometers or refractive index measurement for bodily fluids or clinical diagnostics.

This code shows little relevant recent activity. The opportunities posted between March and July 2026 under the state and local jurisdiction sources examined—primarily Mississippi State University, Texas public entities, Oregon state agencies, Florida counties, and Michigan departments—contain no match to the scope of UNSPSC 41151625. The mismatch suggests either that clinical refractometry is not a category state and local procurement offices actively source, or that when they do purchase such devices, they tag them under broader medical instrument or laboratory equipment codes rather than this specific commodity classification. A business development professional pursuing clinical refractometer sales to state and local entities should verify with target buyers whether this code appears in their internal procurement taxonomies before building pursuit strategy around it.